COLOPLAST SP.ADR 1/10 DK1 (CBH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COLOPLAST SP.ADR 1/10 DK1 (CBH) has a cash flow conversion efficiency ratio of 0.162x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.23 Billion ≈ $2.61 Billion USD) by net assets (€13.80 Billion ≈ $16.14 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
COLOPLAST SP.ADR 1/10 DK1 - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how COLOPLAST SP.ADR 1/10 DK1's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read COLOPLAST SP.ADR 1/10 DK1 total liabilities for a breakdown of total debt and financial obligations.
COLOPLAST SP.ADR 1/10 DK1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COLOPLAST SP.ADR 1/10 DK1 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KT&G Corp
KO:033780
|
0.030x |
|
McCormick & Company Incorporated
NYSE:MKC
|
0.094x |
|
Synnex Corporation
NYSE:SNX
|
0.173x |
|
Penumbra Inc
NYSE:PEN
|
0.043x |
|
Winbond Electronics Corp
TW:2344
|
0.023x |
|
China Shipbuilding Industry Group Power Co Ltd
SHG:600482
|
0.045x |
|
Goertek Inc
SHE:002241
|
-0.010x |
|
GRAB HOLDINGS LTD CL.A
F:A6I
|
0.010x |
Annual Cash Flow Conversion Efficiency for COLOPLAST SP.ADR 1/10 DK1 (2021–2024)
The table below shows the annual cash flow conversion efficiency of COLOPLAST SP.ADR 1/10 DK1 from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of COLOPLAST SP.ADR 1/10 DK1.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | €17.94 Billion ≈ $20.98 Billion |
€2.77 Billion ≈ $3.23 Billion |
0.154x | -36.89% |
| 2023-09-30 | €17.30 Billion ≈ $20.22 Billion |
€4.23 Billion ≈ $4.94 Billion |
0.244x | -60.27% |
| 2022-09-30 | €8.29 Billion ≈ $9.69 Billion |
€5.10 Billion ≈ $5.96 Billion |
0.615x | -5.05% |
| 2021-09-30 | €8.17 Billion ≈ $9.55 Billion |
€5.29 Billion ≈ $6.18 Billion |
0.648x | -- |
About COLOPLAST SP.ADR 1/10 DK1
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, wh… Read more